drugset / Trial / NCT03309150
ATRi Transition Rollover Study
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of the study was to monitor the safety of participant receiving long-term treatment of Berzosertib as monotherapy.
Timeline
- Start
- 2018-01-10
- Primary completion
- 2024-01-26
- Completion
- 2024-01-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Berzosertib | Small molecule | 126 mg | Intravenous |
Indications
No indication recorded.